172 related articles for article (PubMed ID: 14696122)
1. Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man.
Lotz C; Ferreira EA; Drexler I; Mutallib SA; Huber C; Sutter G; Theobald M
Int J Cancer; 2004 Feb; 108(4):571-9. PubMed ID: 14696122
[TBL] [Abstract][Full Text] [Related]
2. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
[TBL] [Abstract][Full Text] [Related]
3. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
5. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.
Colella TA; Bullock TN; Russell LB; Mullins DW; Overwijk WW; Luckey CJ; Pierce RA; Restifo NP; Engelhard VH
J Exp Med; 2000 Apr; 191(7):1221-32. PubMed ID: 10748239
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
8. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
9. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells.
Kondo E; Maecker B; Draube A; Klein-Gonzalez N; Shimabukuro-Vornhagen A; Schultze JL; von Bergwelt-Baildon MS
Int J Cancer; 2009 Nov; 125(10):2474-8. PubMed ID: 19681121
[TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
11. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
Kang X; Kawakami Y; el-Gamil M; Wang R; Sakaguchi K; Yannelli JR; Appella E; Rosenberg SA; Robbins PF
J Immunol; 1995 Aug; 155(3):1343-8. PubMed ID: 7543520
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
13. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
14. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
Stanislawski T; Voss RH; Lotz C; Sadovnikova E; Willemsen RA; Kuball J; Ruppert T; Bolhuis RL; Melief CJ; Huber C; Stauss HJ; Theobald M
Nat Immunol; 2001 Oct; 2(10):962-70. PubMed ID: 11577350
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen.
Hernández J; Ko A; Sherman LA
J Immunol; 2001 Mar; 166(6):3908-14. PubMed ID: 11238635
[TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
17. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
18. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
20. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.
Brichard VG; Herman J; Van Pel A; Wildmann C; Gaugler B; Wölfel T; Boon T; Lethé B
Eur J Immunol; 1996 Jan; 26(1):224-30. PubMed ID: 8566071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]